An example of this situation is crizotinib, which is still being tested for its original intended indication as a treatment for anaplastic large-cell lymphoma via its known target, the MET kinase, and was repositioned for the treatment of non-small-cell lung cancer via a new target, the EML4-ALK oncogene (1). Here, EML4 is linked to anaplastic large cell lymphoma.